Cormorant Asset Management acquired 950,000 shares of Dianthus Therapeutics for approximately $55 million in Q1 2026, despite the stock already surging 350% over the past year. The clinical-stage biotech company, which develops monoclonal antibody therapies for severe autoimmune diseases, recently achieved positive Phase 3 trial results and maintains a strong $1.2 billion cash position, suggesting potential for further upside.

Nanjing Leads Biolabs and partner Dianthus Therapeutics announced that LBL-047, a bifunctional fusion protein targeting plasmacytoid dendritic cells and B cell function, has been selected for clinical development in three autoimmune indications: Sjögren's disease, systemic lupus erythematosus, and dermatomyositis. A Phase 1 study initiated in December 2025 is expected to yield results in the second half of 2026. Dianthus recently raised $719 million to support global development of the asset.

Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares worth approximately $739,000 on April 9, 2026, through an option exercise and immediate sale under a Rule 10b5-1 plan. The transaction reduced his direct common stock holdings to zero, though he retains 71,776 unexercised stock options. The sale appears to be routine liquidity management rather than a strategic exit, especially given the company's recent positive phase 3 trial results for its lead candidate claseprubart.

Ryan Savitz, CFO of Dianthus Therapeutics, sold 114,367 shares worth $9.49 million on March 31, 2026, exercising stock options and liquidating his entire direct common stock holdings. The sale occurred under a Rule 10b5-1 plan following the company's impressive 402% stock price gain over the past year. Savitz retains 90,399 stock options, and the company's lead candidate DNTH103 is on track for phase 3 trials mid-2026.

Dianthus Therapeutics announced the pricing of an upsized underwritten public offering of 7.3 million shares at $81.00 per share and pre-funded warrants, generating approximately $625 million in gross proceeds. The company plans to use the funds to advance clinical and preclinical development activities, commercial readiness, and general corporate purposes. The offering is expected to close on March 12, 2026.

Dianthus Therapeutics announced a conference call and webcast scheduled for March 9, 2026 to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial evaluating claseprubart for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The clinical-stage biotech company is presenting data on its investigational therapy for severe autoimmune diseases.

The generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence projected. These emerging therapies represent a shift toward mechanism-driven treatments targeting refractory disease and improving long-term disease control.

Dianthus Therapeutics CFO Ryan Savitz sold 20,000 shares worth $903,600 on December 4, 2025, completely eliminating his direct equity holdings. The sale was executed through exercise and immediate sale of vested stock options at a weighted average price of $45.18 per share. Despite the insider selling, the stock has retreated from its 52-week high of $45.45 but remains around $38, with analyst estimates suggesting a one-year target of $63.

Dianthus Therapeutics, a clinical-stage biotech company focused on severe autoimmune diseases, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Marino Garcia will present a corporate overview and meet with investors. The company is also advancing its lead candidate LBL-047 (DNTH212), a bifunctional fusion protein for systemic lupus erythematosus, into Phase 1 trials.

Dianthus Therapeutics reported successful Phase 2 trial results for claseprubart in generalized Myasthenia Gravis, demonstrating promising treatment effects and announcing plans for a Phase 3 trial in 2026.

Dianthus Therapeutics has entered an exclusive licensing agreement with Leads Biolabs for DNTH212, a bifunctional fusion protein targeting autoimmune diseases. The agreement involves up to $38 million in initial payments and potential milestone payments up to $962 million, with Dianthus gaining global rights outside Greater China.

Dianthus Therapeutics is conducting a public offering of 6,487,879 common stock shares and pre-funded warrants, expecting to raise approximately $251 million to support preclinical and clinical development activities.